查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1750795

多西他赛市场规模、份额、趋势分析报告：按适应症、分销管道、地区、细分市场预测，2025-2030 年

Docetaxel Market Size, Share & Trends Analysis Report By Indication (Breast Cancer, Non-Small Cell Lung Cancer, Hormone Refractory Prostate Cancer, Gastric Adenocarcinoma), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

多西他赛市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，全球多西他赛市场规模预计到 2030 年将达到 18.5 亿美元，预测期内的复合年增长率为 5.75%。全球癌症发病率上升推动了多西他赛市场的发展，尤其是乳癌、肺癌和前列腺癌，儘管增长幅度不大，但多西他赛仍然被用作这些疾病的一线或二线治疗药物。虽然由于标靶治疗药物的普及而导致扩张受到限制，但筛检项目的改进、癌症意识的提高以及对具有成本效益的化疗的需求都提高了该药物的相关性。从 2025 年到 2030 年，乳癌市场预计将以 5.69% 的复合年增长率成长，达到 6.1108 亿美元，而荷尔蒙难治性前列腺癌和胃腺癌预计将以中等速度增长。

多西他赛的临床整合依然强劲。例如，预计到2025年，美国乳癌病例数将超过31.9万例。早期发现的5年存活率高达99%，筛检工作支持在转移性和早期治疗中持续使用多西他赛。同样，非小细胞肺癌 (NSCLC) 和激素抗性前列腺癌的高发生率也支持了持续的需求。随着学名药和特殊製剂的推出，市场片段化也加剧。 2025年2月，Zydus Lifesciences与珠海北海生物科技公司签署了BEIZRAY在美国的商业化协议，BEIZRAY是一种基于白蛋白的多西他赛製剂，将于2024年根据505(b)(2)途径核准。该药物的年目标销售量为53.1万单位，且不使用合成辅料，因此副作用较少。

此外，研发管线数据显示组合方案仍在持续发展中。 2027年至2032年，多西他赛与DS-1062a（第一三共）、daraxonlasib（Revolution Medicines）和capivasertib（阿斯特捷利康）等药物的联合治疗试验将在非小细胞肺癌、前列腺癌、乳癌和胃癌中进行。这些试验的赞助商包括诺华、赛诺菲、葛兰素史克、石药集团和Mirati，这表明全球公司正在积极参与。

行业趋势表明，口服多西他赛和缓释性他赛等给药方式和剂型正在不断创新，而生物等效性研究和监管审查等壁垒则阻碍了新进入者。儘管学名药已上市，但严格的标准和根深蒂固的竞争决定了行业格局。总体而言，多西他赛仍然是肿瘤治疗方案的核心组成部分，这得益于全球临床应用、持续的研发管线兴趣以及不断发展的伙伴关係。

多西他赛市场报告重点

  • 从适应症来看，乳癌在多西他赛产业占据主导地位，占 2024 年收入份额的 33.11%。这种增长可以归因于全球范围内的高盛行率、完善的治疗方案以及多西他赛在治疗中的强大临床疗效。
  • 根据销售管道，医院药局占据市场主导地位，2024 年的销售份额为 56.00%，这得益于其在管理癌症治疗通讯协定和实施化疗的核心作用。
  • 主要市场参与者包括 Phyton Biotech LLC、Rochem International Inc.、Alchem International Pvt Ltd、LGM Pharma、HRV Global Life Sciences 等。
  • 2025年2月，诺和诺德宣布美国食品药物管理局（FDA）宣布非小细胞肺癌 (NSCLC) 和乳癌供不应求结束，确认美国药物供应已满足需求。该公司投资65亿美元扩大生产，并推出了基于人工智慧的「寻找我的药物」应用程式。诺和诺德将警告民众警惕假药，并强调负责任地使用FDA核准的多西他赛药物。

目录

第一章调查方法与范围

第二章执行摘要

3. 多西他赛市场变数、趋势和范围

  • 市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

4. 多西他赛市场：适应症业务分析

  • 2024年及2030年的指示市场占有率
  • 指示细分仪表板
  • 市场规模、预测与趋势分析（2018-2030 年）
  • 乳癌
  • 非小细胞肺癌（NSCLC）
  • 激素抗性前列腺癌
  • 胃腺癌
  • 头颈部鳞状细胞癌

5. 多西他赛市场：分销通路业务分析

  • 2024年及2030年分销通路市场占有率
  • 分销通路细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析（2018-2030 年）
  • 医院药房
  • 零售药局
  • 网路药局

6. 多西他赛市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模与预测趋势分析：
  • 北美洲
    • 2018-2030年各国情况
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Phyton Biotech LLC
    • Rochem International Inc
    • Alchem International Pvt Ltd
    • LGM Pharma
    • HRV Global Life Sciences
    • Tenatra Chemie
    • Teva Active Pharmaceutical Ingredients（TAPI）
    • Arch Pharmalabs
    • Aspen Pharmacare
    • ChemGenix Laboratories Pvt Ltd
    • Cipla Ltd
Product Code: GVR-4-68040-572-6

Docetaxel Market Growth And Trends

The global docetaxel market size is anticipated to reach USD 1.85 billion by 2030, growing at a CAGR of 5.75% during the forecast period, according to a new report by Grand View Research, Inc. Despite moderate growth, the market remains sustained by the rising global cancer burden, particularly in breast, lung, and prostate cancers-diseases where docetaxel continues to be used as a first- or second-line treatment. While the increasing adoption of targeted therapies limits expansion, improved screening programs, heightened cancer awareness, and demand for cost-effective chemotherapy contribute to the drug's relevance. From 2025 to 2030, the breast cancer segment is projected to grow at 5.69% CAGR, reaching USD 611.08 million, while hormone-refractory prostate cancer and gastric adenocarcinoma are forecast to grow at a moderate growth rate.

Clinical integration of docetaxel remains strong. For instance, in 2025, breast cancer cases in the U.S. are expected to surpass 319,000. With a 99% five-year survival when detected early, screening initiatives support consistent docetaxel use in metastatic and early-stage therapies. Similarly, high incidence of non-small cell lung cancer (NSCLC) and hormone-resistant prostate cancer supports sustained demand. Fragmentation is also increasing due to product launches by generics and specialty formulations. In February 2025, Zydus Lifesciences entered a U.S. commercialization agreement with Zhuhai Beihai Biotech for BEIZRAY-an albumin-based docetaxel formulation approved via the 505(b)(2) pathway in 2024. With an annual target volume of \~531,000 units, the drug avoids synthetic excipients to reduce side effects.

Moreover, pipeline data suggest continued development in combination regimens. Between 2027 and 2032, trials involving docetaxel with agents such as DS-1062a (Daiichi Sankyo), daraxonrasib (Revolution Medicines), capivasertib (AstraZeneca), and others target NSCLC, prostate, breast, and gastric cancers. These studies involve sponsors like Novartis, Sanofi, GSK, CSPC, and Mirati, indicating active engagement from global players.

Industry trends show innovation in delivery and formulation, such as oral and extended-release docetaxel, while barriers like bioequivalence testing and regulatory scrutiny moderate new entries. Despite the availability of generics, stringent standards and established competition shape the landscape. Overall, docetaxel remains a core component in oncology protocols, supported by global clinical use, ongoing pipeline interest, and evolving partnerships.

Docetaxel Market Report Highlights:

  • Based on indication, breast cancer dominated the docetaxel industry, accounting for 33.11% of the revenue share in 2024. This growth is driven by high global prevalence, established treatment protocols, and strong clinical efficacy of docetaxel in therapy.
  • Based on distribution channel, hospital pharmacies led the market and accounted for a revenue share of 56.00% in 2024, due to their central role in managing cancer treatment protocols and administering chemotherapy.
  • Key market players include Phyton Biotech LLC, Rochem International Inc., Alchem International Pvt Ltd, LGM Pharma, and HRV Global Life Sciences.
  • In February 2025, Novo Nordisk announced the FDA has declared the Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer shortage over, confirming U.S. supply meets demand. The company invested USD 6.5 billion to expand production and launched the AI-powered Find My Meds app. Novo Nordisk warns against counterfeit drugs and emphasizes responsible use of its FDA-approved docetaxel medicines.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Docetaxel Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Docetaxel Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2030
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
  • 4.4. Breast Cancer
    • 4.4.1. Breast Cancer Market, 2018 - 2030 (USD Million)
  • 4.5. Non-Small Cell Lung Cancer (NSCLC)
    • 4.5.1. Non-Small Cell Lung Cancer (NSCLC) Market, 2018 - 2030 (USD Million)
  • 4.6. Hormone Refractory Prostate Cancer
    • 4.6.1. Hormone Refractory Prostate Cancer Market, 2018 - 2030 (USD Million)
  • 4.7. Gastric Adenocarcinoma
    • 4.7.1. Gastric Adenocarcinoma Market, 2018 - 2030 (USD Million)
  • 4.8. Squamous Cell Carcinoma of the Head and Neck
    • 4.8.1. Squamous Cell Carcinoma of the Head and Neck Market, 2018 - 2030 (USD Million)

Chapter 5. Docetaxel Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2030
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacies
    • 5.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 6. Docetaxel Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. North America Docetaxel Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Docetaxel Market Estimates and Forecasts, 2017 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Docetaxel Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Phyton Biotech LLC
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Rochem International Inc
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Alchem International Pvt Ltd
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. LGM Pharma
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. HRV Global Life Sciences
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Tenatra Chemie
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Teva Active Pharmaceutical Ingredients (TAPI)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. Arch Pharmalabs
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Aspen Pharmacare
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. ChemGenix Laboratories Pvt Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
    • 7.5.11. Cipla Ltd
      • 7.5.11.1. Overview
      • 7.5.11.2. Financial Performance
      • 7.5.11.3. Product Benchmarking
      • 7.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global docetaxel market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 5 Global docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 North America docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 U.S docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 10 U.S docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 11 Canada docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 12 Canada docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13 Mexico docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Mexico docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Europe docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 18 UK docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 19 UK docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 20 Germany docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Germany docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 France docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 23 France docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 24 Italy docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Italy docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 26 Spain docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Spain docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Norway docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Norway docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30 Denmark docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 31 Denmark docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 32 Sweden docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Sweden docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Japan docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Japan docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 39 China docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 40 China docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 41 India docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 42 India docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Australia docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Australia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 45 South Korea docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 46 South Korea docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 Thailand docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 48 Thailand docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 49 Latin America docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Latin America docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 52 Brazil docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Brazil docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54 Argentina docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 55 Argentina docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Docetaxel market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 South Africa docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 60 South Africa docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 63 UAE docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 64 UAE docetaxel market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Kuwait docetaxel market, by indication, 2018 - 2030 (USD Million)
  • Table 66 Kuwait docetaxel market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Docetaxel market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Docetaxel market dynamics
  • Fig. 12 Docetaxel market: Porter's five forces analysis
  • Fig. 13 Docetaxel market: PESTLE analysis
  • Fig. 14 Product market, 2018 - 2030 (USD Million)
  • Fig. 15 Breast Cancer market, 2018 - 2030 (USD Million)
  • Fig. 16 Non-Small Cell Lung Cancer (NSCLC) market, 2018 - 2030 (USD Million)
  • Fig. 17 Hormone Refractory Prostate Cancer market, 2018 - 2030 (USD Million)
  • Fig. 18 Gastric Adenocarcinoma market, 2018 - 2030 (USD Million)
  • Fig. 19 Squamous Cell Carcinoma of the Head and Neck market, 2018 - 2030 (USD Million)
  • Fig. 20 Distribution Channel market, 2018 - 2030 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 23 Online Pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 24 Docetaxel market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 33 Europe docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 50 Asia Pacific docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 63 Latin America docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 68 MEA docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait docetaxel market, 2018 - 2030 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework